CD19-CAR-T ProTcell / Smart Immune, Memorial Sloan-Kettering Cancer Center - LARVOL DELTA

Smart Immune Announces Oral Presentation of Cell-Fate Plasticity Data of its T-cell Progenitor-Based Therapy Platform (ProTcell) at ASGCT 2022 (GlobeNewswire) - "The data presented demonstrates that despite high expression of BCL11B (in 94.1% of ProTcell™), a protein that locks T cells into their fate, half of ProTcell™ express CD161, an early innate lymphoid cell (ILC) marker suggesting a T/NK dual potential in such cells. Innate lymphoid cells (ILCs) are innate counterparts of T cells that contribute to immune responses by secreting effector cytokines and regulating the functions of other innate and adaptive immune cells. NK cells are a class of ILCs important for their cytolytic role against viruses and tumor cells....These specific culture conditions enable efficient differentiation of ProTcell™ product into high numbers (~10,000 fold expansion) of fully potent, highly pure (>90%) NK cells with no mature T cell contaminants."

Preclinical • Hematological Malignancies • Oncology